BCA
BBIO icon

Berman Capital Advisors’s BridgeBio Pharma BBIO Stock Holding History

Berman Capital Advisors’s Portfolio BBIO Stock Details BBIO Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		$1K Buy
+24
New +$1.29K ﹤0.01% 1808

Other funds holding BBIO

KKRC
Kohlberg Kravis Roberts & Co New York $5.35B AUM 63.01% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PA
Perceptive Advisors New York $5.12B AUM 314.02% 1-Year Est. Return
ACM
Aisling Capital Management New York $476M AUM 128.63% 1-Year Est. Return
HA
HHLR Advisors Grand Cayman, Cayman Islands $1.67B AUM 7.53% 1-Year Est. Return
AIG
American International Group New York $609M AUM 23.67% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Berman Capital Advisors's BBIO Position: Q3 2021 in Review

Berman Capital Advisors opened a new position in BridgeBio Pharma (BBIO) in Q3 2021: 24 shares worth $1K. The stake represents ﹤0.01% of the portfolio and ranks #1808 among its holdings.

210 funds tracked by Wall St. Rank hold BBIO as of Q3 2021.

  • Berman Capital Advisors held 24 shares of BridgeBio Pharma worth $1K as of Q3 2021.
  • BridgeBio Pharma was a new Berman Capital Advisors position in Q3 2021.
  • BridgeBio Pharma made up ﹤0.01% of Berman Capital Advisors's portfolio in Q3 2021, its #1808 holding.
  • 210 funds tracked by Wall St. Rank held BridgeBio Pharma as of Q3 2021.

Based on Berman Capital Advisors's 13F filing for Q3 2021, filed 7 Oct 2021.